BCL2A1 and nasopharyngeal carcinoma: Treatment with A-1331852 and not ABT-199, sensitized both sgBFL-1#1 and sgBFL-1#2 cells to the drug, indicating that BFL-1 and BCL-XL may be necessary for NPC cell survival.